Barclays began coverage on shares of Hill-Rom (NYSE:HRC) in a research report issued on Monday, October 15th, Marketbeat Ratings reports. The firm set an “equal weight” rating and a $95.00 price target on the medical technology company’s stock. Barclays’ target price would suggest a potential downside of 2.21% from the company’s previous close.
A number of other research analysts have also recently issued reports on the company. Northcoast Research reissued a “buy” rating and set a $104.00 price objective on shares of Hill-Rom in a report on Tuesday, July 31st. Zacks Investment Research cut Hill-Rom from a “buy” rating to a “hold” rating in a report on Wednesday, August 1st. ValuEngine raised Hill-Rom from a “hold” rating to a “buy” rating in a report on Tuesday, July 31st. KeyCorp lifted their price objective on Hill-Rom from $97.00 to $115.00 and gave the company an “overweight” rating in a report on Tuesday, July 17th. Finally, Raymond James lifted their price objective on Hill-Rom from $97.00 to $100.00 and gave the company an “outperform” rating in a report on Monday, July 30th. Five analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $100.00.
Shares of Hill-Rom stock traded down $0.87 during midday trading on Monday, hitting $97.15. The company had a trading volume of 501,078 shares, compared to its average volume of 701,448. The company has a market cap of $6.45 billion, a price-to-earnings ratio of 20.45, a PEG ratio of 1.34 and a beta of 0.90. The company has a current ratio of 1.74, a quick ratio of 1.30 and a debt-to-equity ratio of 1.11. Hill-Rom has a 1-year low of $75.68 and a 1-year high of $98.96.
Several institutional investors have recently bought and sold shares of HRC. Bank of Montreal Can acquired a new position in shares of Hill-Rom during the 2nd quarter worth about $148,571,000. Amundi Pioneer Asset Management Inc. grew its position in shares of Hill-Rom by 10,137.2% in the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 392,289 shares of the medical technology company’s stock valued at $34,128,000 after purchasing an additional 388,457 shares during the period. Jennison Associates LLC grew its position in shares of Hill-Rom by 47.0% in the 3rd quarter. Jennison Associates LLC now owns 978,335 shares of the medical technology company’s stock valued at $92,355,000 after purchasing an additional 312,771 shares during the period. BTIM Corp. acquired a new position in shares of Hill-Rom in the 2nd quarter valued at approximately $19,352,000. Finally, Millennium Management LLC grew its position in shares of Hill-Rom by 32.3% in the 2nd quarter. Millennium Management LLC now owns 583,635 shares of the medical technology company’s stock valued at $50,975,000 after purchasing an additional 142,654 shares during the period. Institutional investors own 80.65% of the company’s stock.
Hill-Rom Company Profile
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It provides medical surgical beds, intensive care unit beds, bariatric patient beds, lifts and other devices, non-invasive therapeutic products and surfaces, and communications technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
Further Reading: How does inflation affect different investments?
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.